Details of the Drug Combination

General Information of Drug Combination (ID: DC9R60D)

Drug Combination Name
Eribulin Lenvatinib
Indication
Disease Entry Status REF
Leiomyosarcoma Phase 1 [1]
Component Drugs Eribulin   DM1DX4Q Lenvatinib   DMB1IU4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Eribulin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Liposarcoma 2B59 Approved [3]
Eribulin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Eribulin Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Indication(s) of Lenvatinib
Disease Entry ICD 11 Status REF
Thyroid cancer 2D10 Approved [4]
Thyroid gland follicular carcinoma N.A. Approved [5]
Thyroid gland papillary carcinoma N.A. Approved [5]
Hepatocellular carcinoma 2C12.02 Phase 3 [6]
Renal cell carcinoma 2C90 Phase 3 [7]
Melanoma 2C30 Phase 2 [6]
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
Ovarian cancer 2C73 Phase 1 [8]
Non-small-cell lung cancer 2C25.Y Application submitted [7]
Lenvatinib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [8]
------------------------------------------------------------------------------------
Lenvatinib Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [11]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Cancer DC95HHD N. A. Phase 2 [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03526679) Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6813).
3 Eribulin FDA Label
4 FDA Approved Drug Products from FDA Official Website. 2018. Application Number: (ANDA) 208627.
5 Lenvatinib FDA Label
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
9 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
10 Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16.
11 Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep. 2019 Apr 1;9(1):5404.
12 ClinicalTrials.gov (NCT02640508) Eribulin and Lenvatinib in Advanced Solid Tumors